NUST MISIS scientists' anticancer drug doubles lifetime of sick animals

IMAGE: Laboratory works. view more 

Credit: © NUST MISIS

A research team from NUST MISIS and Pirogov Russian National Research Medical University (RNRMU) has successfully conducted preclinical trials of a new anticancer drug based on magnetite nanoparticles. In the test results, the lifetime of sick mice who were given the drug was doubled. The research results have been published in Nanomedicine.

This innovative drug is a combination of two components: spherical nanoparticles of magnetite, which contain a cytostatic drug (a toxic substance that destroys tumor cells), and a vector molecule that delivers the drug to its destination. Essentially, the molecule leads the poisoned particle specifically to the affected organ, ensuring that healthy tissues are not exposed.

&laquoNUST MISIS scientists, led by Maxim Abakumov, Candidate of Technical Sciences and Head of the NUST MISIS Biomedical Nanomaterials Laboratory, have been working with magnetite nanoparticles for four straight years, and they’re [now] using them to create anticancer drugs. Currently, the research team is working on the preparation of the preclinical trials stage, which are planned for 2019», said Alevtina Chernikova, Rector of NUST MISIS.

The vector molecule is an antibody to the protein of the &laquovascular endothelial growth factor» – a signaling


Article originally posted at

Click here for the full story


Privacy Policy / Terms Of Use

       Powered by MMD